Breaking News


Effects of a new synbiotic mixture on disease activity in pediatric atopic dermatitis


A 12-week, multicenter, randomized, double-blind, placebo-controlled trial in 90 infants (aged < 7 months) with moderate-severe atopic dermatitis (AD) assessed the effects of a synbiotic mixture on the severity of AD, quality of life, topical corticosteroid use and intercurrent illness.  The symbiotic mixture was Immunofortis® (a hydrolyzed formula with Bifidobacterium breve M16-V and a short-chain galacto/long-chain fructo-oligosaccharide mixture). The AD group received the same formula without the synbiotics. AD severity was measured by the SCORing Atopic Dermatitis (SCORAD) index. Although SCORAD scores decreased significantly in both groups versus baseline, there were no statistically significant differences between groups. However, in a subgroup of infants (n = 50) with increased total or specific IgE, SCORAD ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list